Rodman & Renshaw Begins Coverage on Aytu Bioscience Inc (AYTU)

Rodman & Renshaw initiated coverage on shares of Aytu Bioscience Inc (OTC:AYTU) in a research report report published on Monday. The firm issued a buy rating and a $9.00 price target on the stock.

Aytu Bioscience (OTC:AYTU) opened at 3.40 on Monday. The stock’s market cap is $17.24 million. The company’s 50 day moving average is $3.64 and its 200-day moving average is $4.79. Aytu Bioscience has a 1-year low of $3.01 and a 1-year high of $57.00.

Aytu Bioscience Company Profile

Aytu BioScience, Inc is a commercial-stage healthcare company focused on acquiring, developing and commercializing products in the field of urology. The Company focuses on hypogonadism, prostate cancer, urinary tract infections and male infertility. The Company markets ProstaScint (capromab pendetide), a radio imaging agent indicated to detect the prostate specific membrane antigen (PSMA) in the assessment and staging of prostate cancer.

Receive News & Ratings for Aytu Bioscience Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aytu Bioscience Inc and related companies with's FREE daily email newsletter.

Leave a Reply

© 2006-2016 Mideast Time.